© 2021 MJH Life Sciences™ and Psychiatric Times. All rights reserved.
Tardive Dyskinesia
The Profile of Tardive Dyskinesia
June 30, 2021
How do race, age, and gender correlate with the risk of tardive dyskinesia?
Prevention and Early Detection of Tardive Dyskinesia
June 25, 2021
In this custom video series, Rose Mary Xavier, PhD, MS, RN, PMHNP-BC, shares advice that can be helpful to community providers who manage children and adult patients prescribed antipsychotic therapy about screening for involuntary body movements and early signs of tardive dyskinesia.
Treating Tardive Dyskinesia With a VMAT2 Inhibitor
June 25, 2021
In this custom video series, recommendations regarding patient selection and use of VMAT2 inhibitors in patients with tardive dyskinesia based on current clinical guidelines and real-world practice are shared.
VMAT2 Inhibitors for Tardive Dyskinesia
June 25, 2021
In this custom video series, key opinion leaders compare VMAT2 inhibitors available for use to treat patients with tardive dyskinesia.
Anticholinergic Medications and Impaired Cognition
June 25, 2021
In this custom video series, Leslie L. Citrome, MD, MPH, and Rose Mary Xavier, PhD, MS, RN, PMHNP-BC, caution against the use of anticholinergic medications for Parkinson’s disease and comment on the use of alternative therapies for appropriate patients.
Managing Patients on Antipsychotic Therapy
June 25, 2021
In this custom video series, experts provide insight into strategies that may be helpful to healthcare professionals who manage patients on antipsychotic therapy to best monitor for signs of tardive dyskinesia, with special considerations regarding telepsychiatry.
Assessing Severity of Tardive Dyskinesia
June 25, 2021
In this custom video series, Leslie L. Citrome, MD, MPH, and Rose Mary Xavier, PhD, MS, RN, PMHNP-BC, reference the Abnormal Involuntary Movement Scale (AIMS) rating scale, used to assess the severity of involuntary movements and help diagnose tardive dyskinesia.
Screening for Tardive Dyskinesia and Intervening With VMAT2 Inhibitors
June 25, 2021
In this custom video series, key opinion leaders discuss what to know about the use of antipsychotic therapy and screening for signs of tardive dyskinesia, and starting treatment with a VMAT2 inhibitor.
Case Scenario 1: Patient With Bipolar 1 Disorder Reports New Onset Movements
June 25, 2021
In this custom video series, experts share overall impressions of a female patient with bipolar 1 disorder who develops new onset movements suggesting tardive dyskinesia and the rationale for intervening with VMAT2 therapy.
Case Scenario 2: Patient With Tardive Dyskinesia Prescribed a VMAT2 Inhibitor
June 25, 2021
In this custom video series, Leslie L. Citrome, MD, MPH, and Rose Mary Xavier, PhD, MS, RN, PMHNP-BC, review the case of a male patient with schizophrenia who develops symptoms of tardive dyskinesia and comments on the appropriateness for intervening with VMAT2 inhibitor therapy.